Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 11, 2011

Sosei Pays BioAlliance $3M Up Front for Japanese Rights to Oropharyngeal Candidiasis Drug

  • Sosei is paying BioAlliance Pharma $3 million up front for Japanese commercialization rights to the latter’s oropharyngeal candidasis drug Loramyc® (miconazole Lauriad™) mucoadhesive buccal tablets. BioAlliance could receive another $15.5 million in commercialization and milestone payments, plus future royalties from sales in Japan. Loramyc is already approved in 28 countries including the EU, U.S. (where it is trade-named Oravig™), and Korea.

    Loramyc is based on BioAlliance’s Lauriad oral delivery technology, which specifically targets the mucus membranes without systemic transfer. In March BioAlliance received €743,000 (roughly $1.1 million) from Fond Unique Interministériel (a French program supporting collaborative research projects) to support research within a €2 million (about $2.9 million) collaborative program that aims to establish proof-of-concept for delivering biological products via the mucosal route. The first potential application will be a peptide delivered using the Lauriad mucoadhesive technology.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »